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Microbial products activate Toll-like receptors and inﬂam-
masomes. Gram-negative bacteria (which dominate the
microbiome of reﬂux esophagitis) produce lipopolysaccha-
ride, a Toll-like receptor-4 ligand. To explore this system’s
contribution to esophageal inﬂammation, we studied
lipopolysaccharide effects on inﬂammasome priming and
activation in esophageal cells.
BACKGROUND & AIMS: Microbial molecular products incite
intestinal inﬂammation by activating Toll-like receptors (TLRs)
and inﬂammasomes of the innate immune system. This system’s
contribution to esophageal inﬂammation is not known. Gram-
negative bacteria, which dominate the esophageal microbiome
in reﬂux esophagitis, produce lipopolysaccharide (LPS), a TLR4
ligand. TLR4 signaling produces pro-interleukin (IL)1b, pro-
IL18, and NOD-like receptor protein 3 (NLRP3), which prime
the NLRP3 inﬂammasome. Subsequent NLRP3 inﬂammasome
activation cleaves caspase-1, inducing secretion of proin-
ﬂammatory cytokines and pyroptosis (inﬂammatory cell death).
We explored LPS effects on NLRP3 inﬂammasome priming and
activation in esophageal cells.
METHODS: We exposed esophageal squamous and Barrett’s
epithelial cells to LPS and measured the following: (1) TLR4,
pro-IL1b, pro-IL18, andNLRP3 expression; (2) caspase-1 activity;
(3) tumor necrosis factor-a, IL8, IL1b, and IL18 secretion; (4)
lactate dehydrogenase (LDH) release (a pyroptosis marker); and
(5)mitochondrial reactive oxygen species (ROS). As inhibitors,we
used acetyl-Tyr-Val-Ala-Asp-CHO for caspase-1, small interfering
RNA for NLRP3, and (2-(2,2,6,6,-Tetramethylpiperidin-1-oxyl-4-
ylamino)-2-oxoethyl)triphenylphosphonium chloride for mito-
chondrial ROS.
RESULTS: Squamous and Barrett’s cells expressed similar
levels of TLR4, but LPS induced TLR4 signaling that increased
tumor necrosis factor-a and IL8 secretion only in Barrett’s cells.
Barrett’s cells treated with LPS showed increased expression of
pro-IL18, pro-IL1b, and NLRP3, and increased mitochondrial
ROS levels, caspase-1 activity, IL1b and IL18 secretion, and LDH
release. Acetyl-Tyr-Val-Ala-Asp-CHO, NLRP3 small interferingRNA, and Mito-TEMPO all blocked LPS-induced IL1b and IL18
secretion and LDH release.
CONCLUSIONS: In Barrett’s cells, LPS both primes and activates
the NLRP3 inﬂammasome, causing secretion of proinﬂammatory
cytokines and pyroptosis. By triggering molecular events
promoting inﬂammation, the esophageal microbiome might
contribute to inﬂammation-mediated carcinogenesis in Barrett’s
esophagus. (Cell Mol Gastroenterol Hepatol 2016;2:439–453;
http://dx.doi.org/10.1016/j.jcmgh.2016.03.006)
Keywords: IL1b; Pyroptosis; Esophageal Squamous Cell; GERD;
Cytokine.
astroesophageal reﬂux disease (GERD) causesGesophageal inﬂammation (reﬂux esophagitis) that
damages the esophageal squamous epitheliumandenables its
replacement by a metaplastic, intestinal-type columnar
epithelium (Barrett’s esophagus).1 GERD-induced chronic
inﬂammation in Barrett’s esophagus is thought to contribute
to the development of esophageal adenocarcinoma, a tumor
whose frequency has increased at an alarming rate in
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kines have been found in biopsy specimens of inﬂamed Bar-
rett’s metaplasia, with especially high levels of interleukin
(IL)1b.4 Mice genetically engineered to express high levels of
IL1b in the esophagus develop esophagitis with a Barrett’s-
like metaplasia that progresses to adenocarcinoma, suggest-
ing that IL1b might play a key role in Barrett’s-associated
tumorigenesis.5 GERD can cause the esophagus to secrete
proinﬂammatory cytokines,6 but there also is reason to
believe that the esophageal microbiome might contribute to
esophageal inﬂammation with production of IL1b.
IL1b and IL18 (another proinﬂammatory cytokine) can
be generated through proteolytic cleavage of their precursor
proteins (pro-IL1b and pro-IL18) by the cysteine protease
caspase 1.7–9 In addition to activating these proin-
ﬂammatory cytokines, caspase-1 can induce pyroptosis, a
unique form of programmed cell death in which the dying
cells release their proinﬂammatory cytoplasmic contents
into the extracellular space, causing further inﬂamma-
tion.7,10 Thus, caspase-1 can play a major role in promoting
inﬂammation, and caspase-1 can be activated by a cyto-
plasmic protein complex called an inﬂammasome.11
Inﬂammasomes contain pattern-recognition receptors
(PRRs) that recognize certain pathogen-associated molecular
patterns (PAMPs) produced by microbes, and certain
damage-associatedmolecular patterns (DAMPs) produced by
damaged cells.12 There are a number of families of PRRs,
including the nucleotide-binding domain, leucine-rich repeat
containing proteins (NOD; NOD-like receptors [NLRs]), and
the absent in melanoma 2 (AIM)-like receptors,12 and
different inﬂammasomes usually are named for the PRRs they
harbor.13 After the sensing of PAMPs or DAMPs, the PRRs
assemble a large macromolecular complex containing the
PRR itself and an adapter protein called apoptosis-associated
speck-like protein containing a caspase recruitment domain
(ASC). This complex activates caspase-1 in canonical inﬂam-
masomes, and/ormurine caspase-11 (caspase-4/-5 in human
beings) in noncanonical inﬂammasomes.13,14
Canonical and noncanonical inﬂammasome activation is
a 2-step process. The ﬁrst step primes the inﬂammasome by
increasing the expression of pro-IL1b and pro-IL18. This
priming step in canonical and noncanonical inﬂammasomes
is virtually identical, and is accomplished by activation of
Toll-like receptors (TLRs), NOD1 or NOD2, or by signaling
through tumor necrosis factor (TNF)-a or IL1.13,14 In
contrast, canonical and noncanonical inﬂammasomes differ
in the second activating step. In canonical inﬂammasomes,
activation involves the sensing of PAMPs or DAMPs by the
PRRs, which then activate caspase-1. The activated caspase-
1 cleaves the pro-IL1b and pro-IL18 produced during the
priming step into mature active forms that are secreted into
the extracellular space. Activated caspase-1 also induces
pyroptosis, which promotes further inﬂammation.13 In
noncanonical inﬂammasomes, the PRRs recognize intracel-
lular lipopolysaccharide (LPS) (a product of gram-negative
bacteria) to activate caspase-11.14 Activated caspase-11
can mediate pyroptosis directly, but the secretion of IL1b
and IL18 induced by caspase-11 is an indirect process that
requires caspase-1, ASC, and the NOD-like receptor protein3 (NLRP3) PRR to convert pro-IL1b and pro-IL18 into their
active forms.14,15
TLRs also are PRRs, and some of the same molecular pat-
terns that activate the PRRs in inﬂammasomes also activate the
TLRs located on the cell surface or in endosomes. In collabo-
ration with inﬂammasomes, TLRs protect against microbial
infection by triggering an innate immune response.16 However,
inappropriate TLR activation can lead to uncontrolled chronic
inﬂammation and promote carcinogenesis.17,18 Chronic
inﬂammation caused by inappropriate TLR activation can, in
some cases, be attributed to disturbances in the local micro-
biome, which is the collection of microbes and their genes that
reside in a biological niche.19 The human microbiome com-
prises bacteria, fungi, protozoa, and viruses, although bacteria
have been the most well characterized and studied.19
In some cell types, LPS produced by gram-negative
bacteria has been shown to function as a PAMP that acti-
vates TLR4 and primes the inﬂammasome (step 1). In
nonesophageal cells, LPS also has been shown to cause
inﬂammasome activation (step 2).13,20,21 Gram-negative
bacteria dominate the esophageal microbiome of patients
with GERD and Barrett’s esophagus,22–24 and one earlier
study found that Barrett’s epithelial cells express TLR4 that
can be activated by LPS.25 In this study, we have explored
the effects of LPS on TLR4 signaling and on priming and
activation of the inﬂammasome in esophageal squamous
and Barrett’s epithelial cells.
Materials and Methods
Esophageal Squamous and Barrett’s Epithelial
Cell Primary Cultures, and Barrett’s Epithelial Cell
Lines
We established primary cultures of esophageal squa-
mous epithelial cells (NES-B3, NES-B10, NES-G2, and NES-
G4) using biopsy specimens of esophageal squamous
epithelium from 4 patients with GERD, and primary cultures
of Barrett’s epithelial cells (BAR-12, BAR-15, and BAR-18)
using biopsy specimens of Barrett’s metaplasia from 3 pa-
tients with nondysplastic Barrett’s esophagus as previously
described.26 We used 2 non-neoplastic, telomerase-immor-
talized Barrett’s epithelial cell lines (BAR-T, BAR-10T) that
were developed in our laboratory27,28 for the mechanistic
studies described later, and we compared the response of
the Barrett’s cell lines to that of the primary cultures of
Barrett’s epithelial cells. These studies were approved by the
Institutional Review Board of the Dallas VA Medical Center.
Primary cultures and BAR-T cell lines were co-cultured with
a ﬁbroblast feeder layer and maintained in growth medium
as previously described.26,27 Primary cultures and cell lines
were maintained at 37C in a 5% CO2 incubator. For indi-
vidual experiments, primary esophageal cells and BAR-T cell
lines were seeded equally into collagen IV–coated wells (BD
Biosciences, San Jose, CA), in the absence of ﬁbroblast feeder
layers, and maintained in growth medium.
LPS and Adenosine Triphosphate Treatment
In preliminary experiments, we treated telomerase-
immortalized, non-neoplastic esophageal squamous29,30
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and 48 hours in concentrations of 0.1, 1, and 10 mg/mL, and
found that the 1 and 10 mg/mL concentrations decreased
cell viability in some of the cell lines at 48 hours. At 24
hours, LPS at a dose of 10 mg/mL reduced cell viability in
BAR-10T cells only. Therefore, we used LPS at a concen-
tration of 1 mg/mL for up to 24 hours for all further ex-
periments in BAR-T cell lines and in primary esophageal
cells. For some studies, Barrett’s cell lines were stimulated
with 100 mg/mL adenosine triphosphate (ATP) (Sigma) for
30 minutes just before the collection of cells for analysis.
Inhibition of TLR4 Signaling
BAR-10T cells were pretreated with 1 mmol/L TAK-242
(CalBiochem, Billerica, MA), a selective TLR4 inhibitor, af-
ter which LPS was added to the TAK-242–containing media
for either 30 minutes or 4 hours.
NLRP3 RNA Interference
BAR-10T cells were plated equally in 24-well tissue
culture plates and transfected using Lipofectamine RNAi-
MAX Regent (Invitrogen, Carlsbad, CA) and OptiMEM (Life
Technologies, Grand Island, NY) with 25 pmol/mL of the
SMARTpool ON-TARGETplus NLRP3 small interfering RNA
(siRNA) (Thermo Scientiﬁc, Waltham, MA) for 72 hours per
the manufacturer’s instructions. As a control, cells were
transfected with ON-TARGETplus nontargeting siRNA #1
(Thermo Scientiﬁc). After transfection, the medium was
removed, and replaced with growth medium. The efﬁciency
of the siRNA for inhibiting NLRP3 expression was deter-
mined by Western blot at 72 hours. siRNA knockdown was
performed in 2 independent experiments.
Measurement of Caspase-1 Activity
Caspase-1 activity was measured using the caspase-1
assay kit (Fluorometric; Abcam, Cambridge, MA), which
recognizes the sequence YVAD, per the manufacturer’s in-
structions. This assay is based on the detection of cleavage
of the substrate YVAD-7-amino-4-triﬂuoromethyl coumarin,
which emits a blue light at 400 nm. Upon cleavage of the
substrate by caspase-1, the free YVAD-7-amino-4-
triﬂuoromethyl coumarin emits a yellow-green ﬂuores-
cence at 505 nm. The fold increase in caspase-1 activity was
determined by comparing the ﬂuorescence intensity be-
tween treated and untreated BAR-T cells. Fluorescence in-
tensity was detected using the Inﬁnite 200 PRO series
multimode microplate reader (Tecan US, Research Triangle
Park, NC). All assays were performed in triplicate in at least
2 independent experiments.
Inhibition of Caspase-1
BAR-10T cells were incubated with 50 or 100 mmol/L
acetyl-Tyr-Val-Ala-Asp-CHO (Ac-YVAD-CHO; Merck Milli-
pore, Guyancourt, France), a potent and speciﬁc inhibitor of
caspase-1,31 with or without 1 mg/mL LPS for 24 hours. All
assays were performed in triplicate in at least 2 indepen-
dent experiments.Mitochondrial Reactive Oxygen
Species Detection
To measure mitochondrial reactive oxygen species (ROS),
the ﬂuorescent probe MitoSOX Red (Life Technologies) was
used as previously described.32 In brief, BAR-10T cells were
placed in 2-well, Lab-Tek II chamber slides (Nalge Nunc,
Rochester, NY)with a chamber volume of 1mL at 1 105 cells
per well. Cells were treated with or without 1 mg/mL LPS for
24 hours, after which the cells were washed 2 times with
phosphate-buffered saline (PBS). Cells were loaded with 5
mmol/LMitoSOXRed for 10minutes at 37C, and thenwashed
2 times with PBS. Cells were ﬁxed in 2% paraformaldehyde
for 3–5 minutes, and washed 2 times with PBS. Then the cells
were stainedwith 40,6-diamidino-2-phenylindole for 1minute
and washed with PBS 3 times. For some studies, cells were
treated with 100 mmol/L Mito-TEMPO (Enzo Life Sciences,
Farmingdale, NY) and LPS for 24 hours followed by loading
with MitoSOX as described earlier. Cells were imaged with a
Leica DM6000 B ﬂuorescence microscope (Leica Micro-
system, Buffalo Grove, IL) and ﬂuorescence was quantitated
using National Institutes of Health ImageJ software (version
1.48; Bethesda, MD) from 5 separate high-power ﬁelds (40)
per well, and then averaged. All assays were performed in at
least 2 independent experiments.
Quantitative and Qualitative
Reverse-Transcription Polymerase
Chain Reaction
Total RNAs were isolated by using the RNeasy Mini kit
(Qiagen, Valencia, CA) per the manufacturer’s instructions,
and quantitated using the Nanophotometer (Implen,
Westlake Village, CA). Reverse-transcription was performed
using the QuantiTect Reverse Transcription kit (Qiagen) per
the manufacturer’s instructions. The primer sequences
(Table 1) were designed using Primer Express (Applied
BioSystems, Foster City, CA) andmanufactured by Integrated
DNA Technologies (Coralville, IA). Each 50-mL polymerase
chain reaction (PCR) reaction contained 1–5 mL of comple-
mentary DNA (corresponding to 25 or 125 ng total RNA), 2.5
mmol/L of each primer (12.5 pmol total), and 25 mL of 2
GoTaq Green Master Mix (Promega, Madison, WI). For
reverse-transcription (RT)-PCR analysis of pro-IL18, PCR
conditions consisted of 95C for 5 minutes followed by 30
cycles at 95C for 30 seconds, 58C for 30 seconds, and 72C
for 30 seconds; for pro-IL1b and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), PCR conditions con-
sisted of 95C for 5 minutes followed by 25 cycles at 95C for
30 seconds, 60C for 30 seconds, and 72C for 30 seconds;
and for NLRP3, PCR conditions consisted of 95C for 5 mi-
nutes followed by 35 cycles at 95C for 30 seconds, 60C for
30 seconds, and 72C for 30 seconds. After ampliﬁcation, PCR
products were electrophoresed on 2% agarose gels and
stained with ethidium bromide. GAPDH transcripts served as
internal controls. All RT-PCR analyses were performed in 2
independent experiments. In addition to conventional PCR,
real-time quantitative RT-PCR (qPCR) was performed using
rapid cycling with the StepOnePlus Real-Time PCR System
and SYBR Green Master Mix (Applied Biosystems). The
Table 1.Oligonucleotide Primers
Primer Sequence, 5’ to 3’ Location Use
ASC-5’
ASC-3’
TCCTGACGGATGAGCAGTA
GGCTGGTGTGAAACTGAAGA
Sense
Antisense
qPCR
AIM2-5’
AIM2-3’
CTCCTGAGTCCTCTGCTAGTTA
ACTCTCCATCTGACAACTTTGG
Sense
Antisense
qPCR
NLRP1-5’
NLRP1-3’
GGTTCAGGGATGCTGGAAATA
CCAAGTGGCCAACGTAGAA
Sense
Antisense
qPCR
NLRP3-5’
NLRP3-3’
GAAGAGGAGTGGATGGGTTTAC
TCTGCTTCTCACGTACTTTCTG
Sense
Antisense
qPCR
NLRC4-5’
NLRC4-3’
CATCCACGAAACTACCTTCAACTCC
GACAAGCAGCAGGAGACTAAT
Sense
Antisense
qPCR
GAPDH-5’
GAPDH-3’
TCCCACCTTTCTCATCCAAG
GTCTGCAAAAGGAGTGAGGC
Sense
Antisense
qPCR and qualitative PCR
Pro-IL1b-5’
Pro-IL1b-3’
AGTAGCAACCAACGGGAAGG
TTGAGGGCGTCATTCAGGAT
Sense
Antisense
Qualitative PCR
Pro-IL18-5’
Pro-IL18-3’
AGATGATGAAAACCTGGAATCAGA
TGTTCTCACAGGAGAGAGTTGA
Sense
Antisense
qualitative PCR
NLRP3-5’
NLRP3-3’
GCTGCGATCAACAGGAGAGA
GCTCACACTCTCACCCAGAC
Sense
Antisense
qualitative PCR
Table 2.Antibodies Used
Antibody Source information Dosage Use
NLRP3 Rabbit monoclonal
(Cell SignalingTechnology)
1:1000
dilution
WB
TLR4 Rabbit monoclonal
(Santa Cruz Biotechnology)
1:500 dilution WB
Phospho–NF-
kB
p65(Ser536)
Rabbit monoclonal
(Cell Signaling Technology)
1:1000
dilution
WB
Total NF-kB Rabbit monoclonal
(Cell Signaling Technology)
1:2000
dilution
WB
Pro-IL1b Goat polyclonal
(R&D Systems)
1:1000
dilution
WB
b-tubulin Mouse monoclonal
(Sigma)
1:2000
dilution
WB
WB, western blot.
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messenger RNAs (mRNAs) are listed in Table 1. The refer-
ence gene GAPDH served as an internal control. The relative
quantity of mRNA was normalized to GAPDH, which was
expressed at similar levels in all samples, using the delta
delta CT method of relative quantiﬁcation, where CT is the
threshold cycle. All qPCR assays were performed in triplicate
in at least 2 independent experiments.
Protein Extraction and Immunoblotting
Total protein was extracted using 200 mL of 1 cell lysis
buffer (Cell Signaling Technology, Danvers, MA) supple-
mented with 0.5 mmol/L phenylmethylsulfonyl ﬂuoride ac-
cording to the manufacturer’s instructions (Cell Signaling
Technology). Protein concentrations were determined using
the BCA-200 Protein Assay kit (Pierce, Rockford, IL). Proteins
were separated by sodium dodecyl sulfate–polyacrylamide
gel electrophoresis, transferred to nitrocellulose membranes,
and incubated with primary antibodies overnight at 4C
(Table 2). Secondary antibody was either goat anti-rabbit,
horse anti-mouse IgG (Cell Signaling Technology), or
donkey anti-goat IgG (Santa Cruz Biotechnology, Santa Cruz,
CA) conjugated with horseradish peroxidase (Cell Signaling
Technology), and chemiluminescence was determined using
the enhanced chemiluminescence detection system (Pierce).
The membranes were stripped and re-probed with mouse
anti–b-tubulin (Sigma) as a loading control. Proteins were
quantiﬁed using ImageJ software version 1.48, and the
relative quantity of protein with respect to the loading con-
trol was calculated. All immunoblots were performed in 2
independent experiments.
Enzyme-Linked Immunosorbent Assays
for IL8, TNF-a, IL1b, and IL18
Supernatants from esophageal cell cultures were
collected and centrifuged to remove cellular debris. Theamounts of IL8, TNF-a, IL1b, and IL18 in the culture
supernatants were determined by using commercially
available, cytokine-speciﬁc enzyme-linked immunosorbent
assays (IL18: MBL, Nagoya, Japan; IL8 and TNF-a: Life
Technologies; or IL1b: R&D Systems, Minneapolis, MN) per
the manufacturer’s instructions. All assays in cell lines were
performed in triplicate in at least 2 independent experiments.
Measurement of Lactate Dehydrogenase
To evaluate pyroptotic cell death, lactate dehydrogenase
(LDH) release in the supernatants was measured using the
Cytotoxicity Detection kit (Roche Applied Science, Indian-
apolis, IN) per the manufacturer’s instructions.33
Data Analyses
Quantitative data are expressed as means ± SEM. Sta-
tistical analyses were performed using an unpaired Student
July 2016 NLRP3 Inﬂammasome in Barrett’s Cells 443t test or, for multiple comparisons, an analysis of variance,
and the Student–Newman–Keuls multiple-comparisons test
using the Instat for Windows statistical software package
(GraphPad Software, San Diego, CA).
P values of .05 or less were considered signiﬁcant for all
analyses.Results
Primary Cultures of Esophageal Squamous and
Barrett’s Epithelial Cells Express Similar Levels of
TLR4, but LPS Induces Secretion of TNF-a and IL8
Only in thePrimaryCultures ofBarrett’sEpithelial Cells
By using Western blot, we found that primary esopha-
geal squamous cells and primary Barrett’s epithelial cells
expressed similar levels of TLR4 (Figure 1A). In some cellFigure 1. Primary cultures of esophageal squamous
epithelial cells (NES-B3, NES-B10, NES-G2, and NES-G4),
and primary cultures of Barrett’s epithelial cells (BAR-12,
BAR-15, and BAR-18), express similar levels of TLR4, but
LPS signiﬁcantly increases secretion of TNF-a and IL8
only in the primary Barrett’s cells. Similar to primary Bar-
rett’s cells, Barrett’s epithelial cell lines (BAR-T and BAR-10T)
also express TLR4 and signiﬁcantly increase secretion of
TNF-a and IL8 in response to LPS. (A) Western blot for basal
expression of TLR4 protein. Numbers represent the relative
quantity of protein with respect to the loading control. (B and
C) Enzyme-linked immunosorbent assays for (B) TNF-a
secretion and (C) IL8 secretion after 24 hours of LPS stimu-
lation. Bar graphs represent the means ± SEM. *P  .05
compared with untreated control. **P  .01 compared with
untreated control. ***P  .0001 compared with untreated
control.types, LPS produced by gram-negative bacteria (which
dominate the esophageal microbiome of GERD
patients22–24) is known to activate TLR4 to increase levels
of inﬂammatory cytokines such as TNF-a and IL8.25,34 We
found that treatment with LPS (1 mg/mL for 24 hours)
caused a signiﬁcant increase in the secretion of TNF-a
(Figure 1B) and IL8 (Figure 1C) in all 3 primary Barrett’s
cell cultures, but not in any of the primary cultures of
squamous cells.
Barrett’s Epithelial Cell Lines Express TLR4, and
LPS Induces Them to Secrete TNF-a and IL8
Similar to our primary Barrett’s epithelial cells, our
telomerase-immortalized Barrett’s epithelial cell lines (BAR-
T and BAR-10T) also expressed TLR4 (Figure 1A). Treat-
ment with LPS (1 mg/mL for 24 hours) signiﬁcantly
increased secretion of TNF-a (Figure 1B) and IL8
(Figure 1C) in both cell lines, as it did in our primary cell
cultures.
Barrett’s Cell Lines Express High Levels of
NLRP3 mRNA, and Barrett’s Cell Lines and
Primary Barrett’s Cells Express Similar Levels
of NLRP3 Proteins
Inﬂammasomes are named for their PRR (eg, NLRP1,
NLRP3, NLRC4, AIM2), and the caspase-1 in the inﬂamma-
some complex can interact with the PRR directly, or indi-
rectly via the adaptor protein ASC.13 By using qPCR, we
assessed the mRNA expression of inﬂammasome PRRs and
ASC in our Barrett’s cell lines. Both BAR-T and BAR-10T
expressed NLRP1, NLRP3, and ASC mRNAs; neither cell
line expressed appreciable levels of NLRC4, and only BAR-T
expressed some AIM2 mRNA (Figure 2A). NLRP3 was the
PRR expressed at the highest mRNA level in the BAR-T and
BAR-10T cell lines. By using Western blot, we found that our
Barrett’s cell lines and primary cultures of Barrett’s
epithelial cells expressed similar levels of NLRP3 protein
(Figure 2B).
LPS Induces Pro-IL1b, Pro-IL18, and NLRP3
mRNA and Protein Expression That Is Dependent
on TLR4 Signaling in Barrett’s Cell Lines
In most cell types, inﬂammasome functioning usually
requires 2 signals. The ﬁrst signal induces the expression of
pro-IL1b and pro-IL18, which primes the inﬂammasome for
activation by the second signal (Figure 2C).13 A prototypical
example of priming is the binding of LPS to TLR4, leading to
activation of nuclear factor-kB (NF-kB) and the transcrip-
tional up-regulation of pro-IL1b, pro-IL18, and NLRP3
mRNAs.13 In BAR-T and BAR-10T cells treated with LPS for
up to 8 hours, RT-PCR showed increased expression of pro-
IL1b, pro-IL18, and NLRP3 mRNA (Figure 3A). Western blot
showed increases in pro-IL1b and NLRP3 protein levels
during 24 hours of treatment with LPS (Figure 3B); anti-
bodies against IL18 failed to detect a signal in our positive
control, which precluded evaluation of IL18 protein levels in
our samples. To conﬁrm the role of TLR4 in this LPS-
Figure 2. Barrett’s cell lines express high levels of NLRP3 mRNA, and the cell lines and primary cultures of Barrett’s
cells express similar level of NLRP3 protein. (A) Representative experiment showing mRNA expression of ASC and
inﬂammasome PRRs (AIM2, NLRP1, NLRP3, and NLRC4) in BAR-T and BAR-10T cell lines. Bar graphs represent the means ±
SEM. (B) Western blot for basal expression of NLRP3 protein in BAR-T and BAR-10T and in primary Barrett’s cell cultures
(BAR-12, BAR-15, and BAR-18). Numbers represent the relative quantity of protein with respect to the loading control.
(C) Schematic showing NLRP3 inﬂammasome priming and activation. The ﬁrst signal induces the expression of pro-IL1b and
pro-IL18, which prime the inﬂammasome for activation by the second signal. In this example, LPS binding to the TLR4
provides the ﬁrst signal that leads to activation of NF-kB and the transcriptional up-regulation of pro-IL1b, pro-IL18, and
NLRP3 mRNAs. The second signal activates the inﬂammasome. In this example, ATP is the stimulus that causes NLRP3 to
associate with ASC, which contains a caspase recruitment domain. This NLRP3 inﬂammasome complex activates caspase-1,
which catalyzes the proteolytic cleavage of pro-IL1b and pro-IL18 to their mature forms, which are secreted from the cell to
elicit an inﬂammatory response. Cleaved caspase-1 also can induce pyroptosis.
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ciﬁc TLR4 inhibitor TAK-242; efﬁciency of this inhibitor was
assessed by Western blot for phospho-p65, a marker of NF-
kB activation. Treatment with TAK-242 eliminated the LPS-
induced increase in phospho-p65 expression (Figure 3C).
Moreover, LPS-mediated increases in expression of pro-
IL1b, pro-IL18, and NLRP3 mRNAwere reduced markedly by
treatment with TAK-242 (Figure 3D), suggesting that
inﬂammasome priming is dependent on TLR4 signaling in
Barrett’s cells.LPS Activates Caspase-1, Causes Secretion
of IL1b and IL18, and Induces Release of
LDH in Barrett’s Cells
After priming, inﬂammasome complex formation and
cleavage of pro–caspase-1 to its active form can be caused
by a number of different stimuli including extracellular
ATP, a prototypical example of an activating signal
(Figure 2C).12 To explore whether ATP can activate
inﬂammasomes in Barrett’s cells, we treated BAR-T and
BAR-10T cells with LPS as a priming signal, and then added
Figure 3. In Barrett’s cell
lines, LPS treatment in-
duces (A) expression of
pro-IL1b, pro-IL18, and
NLRP3 mRNA as deter-
mined by RT-PCR, and
(B) expression of pro-
IL1b and NLRP3 protein
as determined by West-
ern blot. Inhibition of TLR4
signaling by TAK-242
decreases LPS-induced
(C) phosphorylation of p65
protein and (D) pro-IL1b,
pro-IL18, and NLRP3
mRNA expression. (C)
Vehicle-treated control.
July 2016 NLRP3 Inﬂammasome in Barrett’s Cells 445ATP to the media for 30 minutes immediately before col-
lecting the cells for analysis.21 In both cell lines, the com-
bination of LPS and ATP caused a signiﬁcant increase in
caspase-1 activity, in the secretion of the active forms of
IL1b and IL18, and in the release of LDH (an indicator of
pyroptosis) (Figure 4).
LPS alone (without exogenous ATP) has been shown to
both prime and activate the Nlrp3 inﬂammasome in
mouse dendritic cells.21 Indeed, when we treated BAR-T
and BAR-10T cells with only LPS for up to 24 hours,
this treatment also caused a signiﬁcant increase in
caspase-1 activity, secretion of IL1b and IL18, and release
of LDH (Figure 4). Thus, LPS alone or in combination with
exogenous ATP can activate the inﬂammasome in Barrett’sepithelial cell lines. We conﬁrmed these ﬁndings using
primary cultures of Barrett’s cells. As in the cell lines, we
found that LPS alone signiﬁcantly increased the secretion
of IL1b and IL18, and the release of LDH in primary
Barrett’s epithelial cells (Figure 5). These ﬁndings suggest
that it is the NLRP3 inﬂammasome that is activated by
LPS in Barrett’s cells.LPS Causes the Secretion of IL1b and IL18,
and Induces Pyroptosis in Barrett’s Cells via
the NLRP3 Inﬂammasome
To conﬁrm that LPS signals through the NLRP3-
containing inﬂammasome in Barrett’s epithelial cells, we
Figure 4. LPS acti-
vates caspase-1, causes
secretion of IL1b and
IL18, and induces release
of LDH (an indicator of
pyroptosis) in Barrett’s
cell lines. BAR-T and
BAR-10T cells were treated
with LPS for up to 24
hours, with and without
the addition of ATP for 30
minutes just before per-
forming (A) caspase-1
activity assay and (B–D)
enzyme-linked immuno-
sorbent assays for (B) IL1b,
(C) IL18, and (D) LDH
release. Bar graphs repre-
sent the means ± SEM.*P
< .05 compared with non-
treated corresponding
control. **P  .01
compared with nontreated
corresponding control. ***P
 .001 compared with
nontreated corresponding
control.
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Figure 5. LPS alone causes secretion of IL1b and IL18,
and induces release of LDH in primary cultures of Bar-
rett’s epithelial cells (BAR-12, BAR-15, and BAR-18).
Enzyme-linked immunosorbent assays for (A) IL1b secretion,
(B) IL18 secretion, and (C) LDH release after 24 hours of LPS
stimulation. Bar graphs represent the means ± SEM. *P < .05
compared with nontreated control. **P < .001 compared with
nontreated control. ***P < .0001 compared with nontreated
control.
July 2016 NLRP3 Inﬂammasome in Barrett’s Cells 447knocked down NLRP3 in BAR-10T cells using a speciﬁc
siRNA. Figure 6A shows that NLRP3 siRNA blocked NLRP3
protein expression at baseline and after LPS stimulation.
NLRP3 siRNA virtually abolished the LPS-induced increases
in the secretion of IL1b and IL18 and in the release of LDH
in BAR-10T cells (Figure 6B–D). These ﬁndings show that
LPS signals through the NLRP3 inﬂammasome in
Barrett’s epithelial cells. Furthermore, the near-complete
elimination of LPS effects by NLRP3 siRNA suggests that
NLRP3 is the primary LPS-responsive inﬂammasome in
Barrett’s epithelial cells.The Secretion of Proinﬂammatory Cytokines and
the Induction of Pyroptosis Triggered by LPS in
a Barrett’s Cell Line Both Depend on the
Activation of Caspase-1
All inﬂammasomes can activate the protease caspase-1,
which promotes inﬂammation by cleaving pro-IL1b and
pro-IL18 into their active forms and by inducing pyropto-
sis.7,12 To show that the secretion of proinﬂammatory cy-
tokines and the induction of pyroptosis that are induced by
LPS depend on caspase-1 in Barrett’s cells, we treated BAR-
10T cells with LPS in the presence of Ac-YVAD-CHO, a
speciﬁc caspase-1 inhibitor.31 We found that Ac-YVAD-CHO
treatment in concentrations of 50 and 100 mg/mL abolished
the increase in the secretion of IL1b, IL18, and in the release
of LDH by LPS (Figure 7). These ﬁndings show that LPS
signaling through the NLRP3 inﬂammasome leads to
caspase-1 activation, which triggers the release of proin-
ﬂammatory cytokines and induces pyroptosis in Barrett’s
epithelial cells. Furthermore, the almost complete elimina-
tion of LPS effects on pyroptosis by Ac-YVAD-CHO suggests
that LPS induces canonical (caspase-1–mediated) NLRP3
inﬂammasome activation in Barrett’s epithelial cells.
Independent of TLR4 Signaling, LPS Induces
Mitochondrial Production of ROS, Which
Mediate Activation of the NLRP3
Inﬂammasome in a Barrett’s Cell Line
Mitochondrial production of ROS is known to play a
major role in NLRP3 inﬂammasome activation.35 In cultured
mouse astrocytes, LPS has been found to stimulate the
mitochondrial production of ROS that activate the NLRP3
inﬂammasome.20 To explore the role of mitochondrial ROS
in NLRP3 inﬂammasome activation in Barrett’s cells, we
used MitoSox Red to measure ROS superoxide produced in
the mitochondria of BAR-10T cells at baseline and after
stimulation with LPS. LPS treatment caused a signiﬁcant
increase in the intensity of MitoSOX Red immunostaining
(ie, more mitochondrial superoxide) (Figure 8A). This LPS-
induced increase in mitochondrial superoxide was
abolished by treatment with Mito-TEMPO, a mitochondrial-
targeted antioxidant (Figure 8A). Mito-TEMPO also blocked
LPS-induced increases in the secretion of IL1b and IL18, and
in the release of LDH (Figure 8B–D). Inhibition of TLR4
signaling with TAK-242 had no effect on LPS-induced
mitochondrial superoxide (Figure 8E). These ﬁndings
show that LPS activates the NLRP3 inﬂammasome in Bar-
rett’s epithelial cells by increasing mitochondrial production
of ROS in a fashion that is independent of TLR4 signaling. A
schematic model summarizing the mechanisms elucidated
by our study is provided in Figure 9.
Discussion
Our exploration of the effects of LPS on TLR4 signaling
and on priming and activation of the inﬂammasome in
esophageal squamous and Barrett’s epithelial cells have
uncovered several novel ﬁndings. We have shown that,
although esophageal squamous cells and Barrett’s epithelial
Figure 6. LPS causes the
secretion of IL1b and
IL18, and induces pyrop-
tosis in Barrett’s cells by
signaling through the
NLRP3 inﬂammasome.
(A) Representative Western
blot showing that NLRP3
siRNA knocks down
NLRP3 protein expression
both at baseline and after
24 hours of LPS stimula-
tion in BAR-10T cells.
BAR-10T cells transfected
with control siRNA or
NLRP3 siRNA were treated
with LPS for 24 hours, and
enzyme-linked immuno-
sorbent assays were per-
formed for (B) IL1b
secretion, (C) IL18 secre-
tion, and (D) LDH release.
Bar graphs represent the
means ± SEM. **P  .01
compared with nontreated
corresponding control. ***P
 .0001 compared with
nontreated corresponding
control.
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signaling that increases the secretion of TNF-a and IL8 only
in the Barrett’s cells. We have shown that LPS alone
(without exogenous ATP) both primes and activates the
NLRP3 inﬂammasome, events that might enable the gram-
negative bacteria-dominated esophageal microbiome to
contribute to inﬂammation-mediated carcinogenesis in
Barrett’s esophagus. Finally, we have shown that LPS in-
creases mitochondrial production of ROS in a fashion in-
dependent of TLR4 signaling, and that it is those ROS that
mediate canonical, caspase-1–dependent activation of the
NLRP3 inﬂammasome in Barrett’s epithelial cells.
The gut microbiome recently was recognized as a key
factor that inﬂuences both human health and disease.19
Microbial interactions with their hosts have been pro-
posed to contribute to benign disease and carcinogenesis
through effects on inﬂammation, cell proliferation, and the
generation of genotoxic agents.34,36 Microbial interactions
also might contribute to cancer development through effectson immune surveillance, angiogenesis, and cellular meta-
bolism, and, for patients with cancer, the microbiome can
affect host susceptibility to chemotherapeutic drugs.36
However, few studies have addressed the role of the
esophageal microbiome in esophageal disease. Macfarlane
et al23 reported high levels of pathogenic, nitrate-reducing
Camplyobacter species in the esophagus of patients with
Barrett’s metaplasia, but not in control patients. Conceiv-
ably, these bacteria might contribute to esophageal disease
by enhancing the production of damaging, reactive nitrogen
species. Other studies have shown that the esophageal
microbiome of patients with reﬂux esophagitis and Barrett’s
esophagus is dominated by gram-negative bacteria that
produce LPS, the natural ligand of TLR4.22–24
TLRs are critical sensors of the PAMPs produced by viral,
bacterial, and fungal microorganisms. Such PAMPs can
activate TLR signaling, triggering an inﬂammatory response
that might protect the host from microbial invasion.37 TLR4
recognizes PAMPs of the endotoxin LPS, a component of the
Figure 7. LPS signaling through the NLRP3 inﬂammasome
causes caspase-1–dependent increases in the secretion
of IL1b and IL18 and in the release of LDH. Enzyme-linked
immunosorbent assays for (A) IL1b secretion, (B) IL18
secretion, and (C) LDH release in BAR-10T cells treated with
LPS for 24 hours in the presence of 50 or 100 mg/mL of YVAD,
a speciﬁc caspase-1 inhibitor. Bar graphs represent the
means ± SEM. ***P  .001 compared with nontreated
control. þþþP  .001 compared with LPS-treated cells.
Figure 8. LPS increases mitochondrial ROS production,
which activates the NLRP3 inﬂammasome in BAR-10T
cells. (A) MitoSOX Red immunostaining for mitochondrial
ROS in BAR-10T cells treated with LPS. Treatment with
Mito-TEMPO (a mitochondrial-targeted antioxidant) conﬁrms
the mitochondrial origin of the ROS. 40,6-diamidino-2-
phenylindole (DAPI) indicates the number of nuclei in the
same ﬁeld. Scale bar: 50 mmol/L. Quantiﬁcation of MitoSOX
Red ﬂuorescence intensity in BAR-10T cells treated with LPS
and Mito-TEMPO. (B–D) Enzyme-linked immunosorbent as-
says for (B) IL1b secretion, (C) IL18 secretion, and (D) LDH
release in BAR-10T cells treated with LPS and Mito-TEMPO.
(E) MitoSOX Red immunostaining for mitochondrial ROS in
BAR-10T cells treated with LPS and TAK-242. DAPI indicates
the number of nuclei in the same ﬁeld. Scale bar: 50 mmol/L.
Quantiﬁcation of MitoSOX Red ﬂuorescence intensity in BAR-
10T cells treated with LPS and TAK-242. Bar graphs represent
the means ± SEM. *P  .05 compared with nontreated cor-
responding control. **P  .01 compared with nontreated
corresponding control. ***P  .001 compared with nontreated
control. ****P < .0001 compared with nontreated control.
July 2016 NLRP3 Inﬂammasome in Barrett’s Cells 449outer membrane of the gram-negative bacteria16 that
dominate the esophageal microbiome of patients with reﬂux
esophagitis with and without Barrett’s esophagus.22–24
In earlier studies, Verbeek et al25 found TLR4 expression
in esophageal squamous cells and in Barrett’s epithelial cells.
They reported that LPS caused a signiﬁcant increase in the
expression of cyclooxygenase-2 in biopsy specimens of Bar-
rett’s metaplasia that were cultured ex vivo, but not in
similarly cultured biopsy specimens of squamous esophageal
mucosa. In support of our ﬁndings, Verbeek et al25 found that
LPS increased IL8 secretion in the Barrett’s biopsy specimens
but, in contrast to our ﬁndings, they found that LPS also
caused a small, but statistically signiﬁcant, increase in IL8secretion in the squamous biopsy specimens. It is not clear
why Verbeek et al25 found LPS-induced TLR4 signaling in
esophageal squamous tissue when we did not, but this
disparity might be owing to differences in experimental
conditions. We studied squamous epithelial cells in culture,
Figure 8. (continued).
Figure 8. (continued).
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specimens that included inﬂammatory and stromal cells in
addition to epithelial cells. Those nonepithelial cell types also
express TLR4, and the ex vivo model did not distinguish
between TLR4 signaling by epithelial and nonepithelial
cells.25 Thus, the small increase in IL8 secretion induced by
LPS in the squamous biopsy specimens of Verbeek et al25
might have resulted from TLR4 signaling in inﬂammatory
or stromal cells, rather than in squamous cells.
Chronic inﬂammation is well known to be associated
with a number of gastrointestinal tract cancers, but the role
of inﬂammasomes in the development of those malignancies
has not been widely appreciated. There is evidence that
inﬂammasome activation contributes to tumorigenesis in
Helicobacter pylori–associated gastric cancer and in colon
cancer (reviewed by Kolb et al13), but little was known
about the role of inﬂammasomes in Barrett’s esophagus. Wehave shown that Barrett’s cell lines express several
inﬂammasome PRR mRNAs including NLRP1, NLRP3, and
AIM2, but NLRP3 predominates and Barrett’s cell lines and
primary cultures of Barrett’s epithelial cells express similar
levels of NLRP3 protein. In a number of cell types, NLRP3
inﬂammasome functioning requires 2 signals: a priming
signal (eg, LPS binding to TLR4) that induces the expression
of pro-IL1b and pro-IL18, and an activation signal (eg,
extracellular ATP) that results in the secretion of the active
forms of IL1b and IL18 and in the induction of pyroptosis. In
mouse macrophages, NLRP3 inﬂammasome functioning re-
quires LPS for priming and requires extracellular ATP for
activation,21,38 whereas LPS alone (without exogenous ATP)
can both prime and activate the NLRP3 inﬂammasome in
mouse dendritic cells, mouse astrocytes, and human
monocytes.20,21 Because NLRP3 inﬂammasome functioning
in Barrett’s epithelial cells had not been described before, it
was not clear whether 1 or 2 separate signals would be
required. We found that LPS primed the Barrett’s cell
NLRP3 inﬂammasome by up-regulating the expression of
pro-IL1b and pro-IL18. We then added exogenous extra-
cellular ATP to the media as an activation signal positive
Figure 9. Schematic showing how LPS both primes and activates the NLRP3 inﬂammasome in Barrett’s epithelial cells.
LPS provides the ﬁrst signal by activating TLR4, which induces expression of NLRP3, pro-IL1b, and pro-IL18. This primes the
inﬂammasome. LPS also provides the second activating signal by increasing mitochondrial production of ROS. These ROS
activate the NLRP3 inﬂammasome, leading to caspase-1 activation, which triggers the release of proinﬂammatory cytokines
and induces pyroptosis. By triggering molecular events that both prime and activate the NLRP3 inﬂammasome, LPS produced
by the esophageal microbiome might contribute to inﬂammation-mediated carcinogenesis in Barrett’s esophagus.
July 2016 NLRP3 Inﬂammasome in Barrett’s Cells 451control, and found that this combination of LPS and ATP
indeed activated the inﬂammasome, causing a signiﬁcant
increase in caspase-1 activity, in the secretion of the active
forms of IL1b and IL18, and in the release of LDH. We also
found that LPS alone (without exogenous ATP) activated
that inﬂammasome in Barrett’s cells. Thus, in Barrett’s cells,
LPS can both prime and activate the NLRP3 inﬂammasome.
We also showed that a speciﬁc NLRP3 siRNA abolished
these LPS effects, conﬁrming that LPS signals through the
NLRP3 inﬂammasome.
Recently, it was shown that intracellular LPS can activate
caspase-11 directly, which then can activate the NLRP3
inﬂammasome through the noncanonical inﬂammasome
pathway without signaling through TLR4.15 Activation of
caspase-11 by intracellular LPS can cause pyroptosis
directly, but caspase-11–induced secretion of IL1b and IL18
is an indirect process mediated through the NLRP3/
caspase-1 inﬂammasome.15 If the pyroptosis we observed
in our LPS-treated Barrett’s cells was the result of intra-
cellular LPS activating caspase-11, then LPS treatment
should have caused pyroptosis even in the presence of a
caspase-1 inhibitor.39 However, we found that YVAD, a
speciﬁc caspase-1 inhibitor, completely abolished pyropto-
sis in addition to eliminating LPS-mediated secretion of IL1b
and IL18. These ﬁndings suggest that the LPS effects we
observed in our Barrett’s cells all were medicated through
canonical inﬂammasome activation of caspase-1.ROS also have been shown to play a major role in acti-
vating the NLRP3 inﬂammasome, and mitochondrial ROS
production appears to be essential for this process.35,40 In
our studies in Barrett’s cells, MitoSOX Red immunostaining
showed that LPS signiﬁcantly increased mitochondrial ROS
production, which was eliminated by treatment with the
mitochondrial-targeted antioxidant Mito-TEMPO, but not by
treatment with the TLR4 inhibitor TAK-242. These ﬁndings
suggest that the LPS-induced generation of mitochondrial
ROS in Barrett’s cells does not rely on TLR4/NF-kB
signaling. In support of our ﬁndings, a recent study found
that levornidazole (a novel, third-generation, nitromidazole-
derivative antibiotic) blocked activation of the NLRP3
inﬂammasome by suppressing LPS-mediated production of
mitochondrial ROS without affecting LPS-mediated NF-kB
activity.41 In addition, mito-TEMPO abolished LPS-induced
increases in IL1b and IL18 secretion, and in the release of
LDH. These ﬁndings show that LPS causes a TLR4-
independent increase in mitochondrial production of ROS,
which in turn activate the NLRP3 inﬂammasome in Barrett’s
epithelial cells.
In conclusion, our study supports a role for the esoph-
ageal microbiome in activating the NLRP3 inﬂammasome in
Barrett’s esophagus. We have shown that the LPS produced
by gram-negative bacteria in the esophagus can activate
TLR4 signaling in Barrett’s cells, but not in esophageal
squamous cells. We have found that LPS primes the
452 Nadatani et al Cellular and Molecular Gastroenterology and Hepatology Vol. 2, No. 4Barrett’s cell inﬂammasome for activation by inducing the
expression of NLRP3, pro-IL1b, and pro-IL18. Moreover, we
have shown that LPS increases mitochondrial production of
ROS in a fashion independent of TLR4 signaling, and that
those ROS mediate canonical, caspase-1–dependent inﬂam-
masome activation. The activated caspase-1 catalyzes the
proteolytic cleavage of pro-IL1b and pro-IL18 to their
mature, active forms, which are secreted from the cell to
elicit an inﬂammatory response that can be exacerbated by
caspase-1–induced pyroptosis. By triggering molecular
events that both prime and activate the NLRP3 inﬂamma-
some, LPS produced by the esophageal microbiome might
contribute to inﬂammation-mediated carcinogenesis in
Barrett’s esophagus, a biologically signiﬁcant event. This
study suggests the intriguing possibility that manipulation
of the esophageal microbiome could be a novel strategy to
prevent cancer in Barrett’s esophagus.
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